Effect of food on the pharmacokinetics of ropinirole in parkinsonian patients

British Journal of Clinical Pharmacology

Volumn 45, Issue 4, 1998, Pages 412-415

  Brefel, C ^a   Thalamas, C ^b   Rayet, S ^b   Lopez Gil, A ^b   Fitzpatrick, K ^c   Bullman, S ^c   Citerone, D R ^c   Taylor, A C ^c   Montastruc, J L ^a   Rascol, O ^a,b  

^a UNIVERSITÉ PAUL SABATIER   (France)

^b CHU PURPAN   (France)

^c GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Dopaminergic agonsit; Food interaction; Parkinson's disease; Pharmacokinetics; Ropinirole

Indexed keywords

AMITRIPTYLINE; CIPROFIBRATE; ESTRADIOL; FENOFIBRATE; HYDROCHLOROTHIAZIDE; LEVODOPA; LISINOPRIL; LORAZEPAM; NICARDIPINE; PROGESTERONE; ROPINIROLE; SELEGILINE; SOTALOL; ZOPICLONE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMORBIDITY; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIET RESTRICTION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG RECEPTOR BINDING; DRUG SPECIFICITY; FEMALE; FOOD DRUG INTERACTION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; MALE; PARKINSON DISEASE; PRIORITY JOURNAL; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; RECEPTOR AFFINITY;

AGED; ANTIPARKINSON AGENTS; AREA UNDER CURVE; FEMALE; FOOD-DRUG INTERACTIONS; HALF-LIFE; HUMANS; INDOLES; MALE; MIDDLE AGED; PARKINSON DISEASE;

EID: 6844260551     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1998.00704.x     Document Type: Article

References (14)

1. Neuvonen PJ, Kivistö KT. The clinical significance of food-drug interactions: a review. Med J Aust 1989; 150: 36-40.
2. Frankel JP, Kempster PA, Bovingdon M, Webster R, Lees AJ. The effects of oral protein on the absorption of intraduodenal levodopa and motor performance. J Neurol Neurosurg Psychiatry 1989; 52: 1063-1067.
3. Vidaihlet M, Bonnet AM, Belal S, Dubois B, Marie C, Agid Y. Ropinirole without levodopa in Parkinson's disease. Lancet 1990; 336: 316-317.
4. Rascol O, Brooks D, Brunt E, Korczyn A, Poewe W, Stocchi F, on behalf of the 056 Study Group. Ropinirole in the treatment of early Parkinson's disease: a six month interim report of a five year L-dopa control study. Mov Disord 1997; in press.
5. Kleedorfer B, Stern QM, Lees AJ. Ropinirole (SK and F 101468) in the treatment of Parkmson's disease. J Neurol Neurosurg Psychiatry 1991; 54: 938.
6. Rascol O, Lees AJ, Senard JM, Pirtozek Z, Montastruc JL, Fuell D. Ropinirole in the treatment of levodopa induced motor fluctuations in patients with Parkinson's disease. Clin Neuropharmacol 1996; 3: 234-245.
7. Gibb WRG, Lees AJ. The relevance of Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1988; 51: 745-752.
8. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology Minneapolis 1967; 17: 427-442.
9. Saunier JL. Interactions médicaments et alimentation. Therapie 1995; 50: 197-198.
10. Nutt JG, Fellman JH. Pharmacokinetics of levodopa. Clin Neuropharmacol 1984; 7: 35-49.
11. Wade DN, Mearrick PT, Morris JL. Active transport of L-dopa in the intestine. Nature 1973; 242: 463-465.
12. Carter JH, Nutt JG, Wooward WR, Hatcher LF, Trotman TL. Amount and distribution of dietary protein affects clinical response to levodopa in Parkinson's disease. Neurology 1989; 39: 552-556.
13. Drewe J, Mazer N, Abisch E, Krummen K, Keck M. Differential effect of food on kinetics of bromocriptine in a modified release capsule and a conventional formulation. Eur J Clin Pharmacol 1988; 35: 535-541.
14. Ho KY, Thorner MO. Therapeutic application of bromocriptine in endocrine and neurological diseases. Drugs 1988; 36: 67-82.